EarningsQ2 2026 Earnings Report
SUSRF Q2 2026 EPS Results
Actual EPS$0.04
Consensus EPS$0.05
Beat/MissMissed by -<$0.01
One Year Ago EPS-$0.04
SUSRF Q2 2026 Revenue Results
Actual Revenue$25.31M
Expected Revenue$23.80M
Beat/MissBeat by +$1.51M
YoY Revenue Growth+21.69%
Earnings Announcement Details
QuarterQ2 2026
Date08/19/2026
TimeBefore Open
Conference CallWednesday, August 19, 2026
SUSRF Upcoming Earnings
Surgical Science Sweden AB's next earnings date is estimated for November 12, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: robust top-line growth (Q2 revenues +22% reported, +25% local), strong license momentum (+44% YoY), improved gross margin (69%) and adjusted EBIT at target (15%). Management highlighted strategic investments (Tel Aviv production, Hong Kong service hub), product launches, and a broadening robotics customer base. Key risks are acknowledged: China headwinds, lumpy license and development revenues, currency-related revaluation losses, and working-capital timing effects. Management expects the Intuitive revenue impact to be smaller than previously estimated but retains caution on full-year visibility. Overall, positives significantly outweigh the negatives, while some timing and currency uncertainties remain.Company Guidance
Strong Revenue Growth
Q2 revenue SEK 255 million, up 22% reported and 25% in local currencies; first half revenues up 7% reported and 11% in local currencies.
License Revenue Momentum
License revenues SEK 85 million in Q2, up 44% year-over-year; license revenues represented 33% of total revenues for the quarter and the Intuitive attach/renewal performance was better than internal expectations.
Profitability in Line with Targets
Adjusted EBIT of SEK 38 million in Q2, corresponding to a 15% adjusted EBIT margin (in line with the company's financial goal); adjusted EBIT for H1 SEK 77 million or 15%.
Improved Gross Margin
Gross margin improved to 69% in Q2 from 65% in the same period last year; gross margin improvement attributed to a stronger license mix and operational/pricing improvements in the simulator business (gross margin excluding licenses improved several percentage points).
Segment Growth — Educational and Industry
Educational Products grew 19% year-over-year (24% in local currencies); Industry revenues grew 24% (27% in local currencies), supported by strong license performance across multiple robotics customers.
Ultrasound Acceleration
Ultrasound revenues grew 34% year-over-year, reflecting accelerating adoption (POCUS and women's health focus) and progressing integration of the Intelligent Ultrasound acquisition.
Operational Investments and Capacity
Opened APAC service hub in Hong Kong and commissioned a new production facility in Tel Aviv designed for higher volumes and improved productivity; cash position strong with SEK 658 million and no debt.
Improved Cash Performance
Operating cash flow for the first half SEK 81 million (well ahead of prior year), demonstrating cash generation alongside growth.
Commercial & Product Momentum
Launched new suturing module and procedure simulation for RobotiX Express; strong response at SRS conference; broadened robotics customer base (working with most leading robotic surgery companies).
Cost Discipline and OpEx Trends
Sales costs reduced to 19% of sales (down from 28% prior year); admin costs down to 9% of sales (from 11% prior year); annualized remuneration review impact ~SEK 3.5 million per quarter recognized.
SUSRF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed